^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer

    Published date:
    04/05/2021
    Excerpt:
    ...phase IB/II study evaluated sapanisertib, a dual inhibitor of mTOR kinase complexes 1/2, plus exemestane or fulvestrant in postmenopausal women with HR+/HER2- advanced/metastatic breast cancer....Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.
    Secondary therapy:
    fulvestrant; exemestane
    DOI:
    10.1158/1078-0432.CCR-20-4131